Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis

Detalhes bibliográficos
Autor(a) principal: Magalhaes, A.
Data de Publicação: 2012
Outros Autores: Ferreira, K. S. [UNIFESP], Almeida, S. R., Nosanchuk, J. D., Travassos, L. R. [UNIFESP], Taborda, Carlos Pelleschi [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/handle/11600/34357
http://dx.doi.org/10.1128/CVI.05414-11
Resumo: Vaccination with peptide 10 (P10), derived from the Paracoccidioides brasiliensis glycoprotein 43 (gp43), induces a Th1 response that protects mice in an intratracheal P. brasiliensis infection model. Combining P10 with complete Freund's adjuvant (CFA) or other adjuvants further increases the peptide's antifungal effect. Since dendritic cells (DCs) are up to 1,000-fold more efficient at activating T cells than CFA, we examined the impact of P10-primed bone-marrow-derived DC vaccination in mice. Splenocytes from mice immunized with P10 were stimulated in vitro with P10 or P10-primed DCs. T cell proliferation was significantly increased in the presence of P10-primed DCs compared to the peptide. the protective efficacy of P10-primed DCs was studied in an intratracheal P. brasiliensis model in BALB/c mice. Administration of P10-primed DCs prior to (via subcutaneous vaccination) or weeks after (via either subcutaneous or intravenous injection) P. brasiliensis infection decreased pulmonary damage and significantly reduced fungal burdens. the protective response mediated by the injection of primed DCs was characterized mainly by an increased production of gamma interferon (IFN-gamma) and interleukin 12 (IL-12) and a reduction in IL-10 and IL-4 compared to those of infected mice that received saline or unprimed DCs. Hence, our data demonstrate the potential of P10-primed DCs as a vaccine capable of both the rapid protection against the development of serious paracoccidioidomycosis or the treatment of established P. brasiliensis disease.
id UFSP_5c73a890e7ad72d2e9d5ecd0fad26ec1
oai_identifier_str oai:repositorio.unifesp.br:11600/34357
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Magalhaes, A.Ferreira, K. S. [UNIFESP]Almeida, S. R.Nosanchuk, J. D.Travassos, L. R. [UNIFESP]Taborda, Carlos Pelleschi [UNIFESP]Universidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)Albert Einstein Coll Med2016-01-24T14:17:36Z2016-01-24T14:17:36Z2012-01-01Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 19, n. 1, p. 23-29, 2012.1556-6811http://repositorio.unifesp.br/handle/11600/34357http://dx.doi.org/10.1128/CVI.05414-11WOS000298675000005.pdf10.1128/CVI.05414-11WOS:000298675000005Vaccination with peptide 10 (P10), derived from the Paracoccidioides brasiliensis glycoprotein 43 (gp43), induces a Th1 response that protects mice in an intratracheal P. brasiliensis infection model. Combining P10 with complete Freund's adjuvant (CFA) or other adjuvants further increases the peptide's antifungal effect. Since dendritic cells (DCs) are up to 1,000-fold more efficient at activating T cells than CFA, we examined the impact of P10-primed bone-marrow-derived DC vaccination in mice. Splenocytes from mice immunized with P10 were stimulated in vitro with P10 or P10-primed DCs. T cell proliferation was significantly increased in the presence of P10-primed DCs compared to the peptide. the protective efficacy of P10-primed DCs was studied in an intratracheal P. brasiliensis model in BALB/c mice. Administration of P10-primed DCs prior to (via subcutaneous vaccination) or weeks after (via either subcutaneous or intravenous injection) P. brasiliensis infection decreased pulmonary damage and significantly reduced fungal burdens. the protective response mediated by the injection of primed DCs was characterized mainly by an increased production of gamma interferon (IFN-gamma) and interleukin 12 (IL-12) and a reduction in IL-10 and IL-4 compared to those of infected mice that received saline or unprimed DCs. Hence, our data demonstrate the potential of P10-primed DCs as a vaccine capable of both the rapid protection against the development of serious paracoccidioidomycosis or the treatment of established P. brasiliensis disease.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Univ São Paulo, Inst Biomed Sci, Dept Microbiol, São Paulo, BrazilUniv São Paulo, Lab Med Mycol IMT SP LIM53, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Biol Sci, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilUniv São Paulo, Dept Clin & Toxicol Anal, Fac Pharmaceut Sci, São Paulo, BrazilAlbert Einstein Coll Med, Dept Med, Bronx, NY 10467 USAAlbert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USAUniversidade Federal de São Paulo, Dept Biol Sci, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilFAPESP: 2009/15823-7FAPESP: 2010/51423-0CNPq: 470513/2009-8Web of Science23-29engAmer Soc MicrobiologyClinical and Vaccine ImmunologyProphylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000298675000005.pdfapplication/pdf1479089${dspace.ui.url}/bitstream/11600/34357/1/WOS000298675000005.pdfccb37c2ef1360d82dfd37a5863e2f4d1MD51open accessTEXTWOS000298675000005.pdf.txtWOS000298675000005.pdf.txtExtracted texttext/plain36576${dspace.ui.url}/bitstream/11600/34357/2/WOS000298675000005.pdf.txt6d206fcc9c80d1cb256379d8531bdb37MD52open access11600/343572022-09-27 09:48:30.141open accessoai:repositorio.unifesp.br:11600/34357Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:23:19.376696Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
title Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
spellingShingle Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
Magalhaes, A.
title_short Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
title_full Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
title_fullStr Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
title_full_unstemmed Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
title_sort Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
author Magalhaes, A.
author_facet Magalhaes, A.
Ferreira, K. S. [UNIFESP]
Almeida, S. R.
Nosanchuk, J. D.
Travassos, L. R. [UNIFESP]
Taborda, Carlos Pelleschi [UNIFESP]
author_role author
author2 Ferreira, K. S. [UNIFESP]
Almeida, S. R.
Nosanchuk, J. D.
Travassos, L. R. [UNIFESP]
Taborda, Carlos Pelleschi [UNIFESP]
author2_role author
author
author
author
author
dc.contributor.institution.none.fl_str_mv Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Albert Einstein Coll Med
dc.contributor.author.fl_str_mv Magalhaes, A.
Ferreira, K. S. [UNIFESP]
Almeida, S. R.
Nosanchuk, J. D.
Travassos, L. R. [UNIFESP]
Taborda, Carlos Pelleschi [UNIFESP]
description Vaccination with peptide 10 (P10), derived from the Paracoccidioides brasiliensis glycoprotein 43 (gp43), induces a Th1 response that protects mice in an intratracheal P. brasiliensis infection model. Combining P10 with complete Freund's adjuvant (CFA) or other adjuvants further increases the peptide's antifungal effect. Since dendritic cells (DCs) are up to 1,000-fold more efficient at activating T cells than CFA, we examined the impact of P10-primed bone-marrow-derived DC vaccination in mice. Splenocytes from mice immunized with P10 were stimulated in vitro with P10 or P10-primed DCs. T cell proliferation was significantly increased in the presence of P10-primed DCs compared to the peptide. the protective efficacy of P10-primed DCs was studied in an intratracheal P. brasiliensis model in BALB/c mice. Administration of P10-primed DCs prior to (via subcutaneous vaccination) or weeks after (via either subcutaneous or intravenous injection) P. brasiliensis infection decreased pulmonary damage and significantly reduced fungal burdens. the protective response mediated by the injection of primed DCs was characterized mainly by an increased production of gamma interferon (IFN-gamma) and interleukin 12 (IL-12) and a reduction in IL-10 and IL-4 compared to those of infected mice that received saline or unprimed DCs. Hence, our data demonstrate the potential of P10-primed DCs as a vaccine capable of both the rapid protection against the development of serious paracoccidioidomycosis or the treatment of established P. brasiliensis disease.
publishDate 2012
dc.date.issued.fl_str_mv 2012-01-01
dc.date.accessioned.fl_str_mv 2016-01-24T14:17:36Z
dc.date.available.fl_str_mv 2016-01-24T14:17:36Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 19, n. 1, p. 23-29, 2012.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/handle/11600/34357
http://dx.doi.org/10.1128/CVI.05414-11
dc.identifier.issn.none.fl_str_mv 1556-6811
dc.identifier.file.none.fl_str_mv WOS000298675000005.pdf
dc.identifier.doi.none.fl_str_mv 10.1128/CVI.05414-11
dc.identifier.wos.none.fl_str_mv WOS:000298675000005
identifier_str_mv Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 19, n. 1, p. 23-29, 2012.
1556-6811
WOS000298675000005.pdf
10.1128/CVI.05414-11
WOS:000298675000005
url http://repositorio.unifesp.br/handle/11600/34357
http://dx.doi.org/10.1128/CVI.05414-11
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Clinical and Vaccine Immunology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 23-29
dc.publisher.none.fl_str_mv Amer Soc Microbiology
publisher.none.fl_str_mv Amer Soc Microbiology
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
bitstream.url.fl_str_mv ${dspace.ui.url}/bitstream/11600/34357/1/WOS000298675000005.pdf
${dspace.ui.url}/bitstream/11600/34357/2/WOS000298675000005.pdf.txt
bitstream.checksum.fl_str_mv ccb37c2ef1360d82dfd37a5863e2f4d1
6d206fcc9c80d1cb256379d8531bdb37
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1783460284620341248